Preview

Рецепт

Расширенный поиск

Ожирение: современные возможности лечения у взрослых

https://doi.org/10.34883/PI.2020.2.2.041

Полный текст:

Аннотация

В статье представлены сведения о распространенности ожирения и избыточной массы тела в различных странах мира с учетом половой принадлежности. Проанализированы современные возможности коррекции избыточной массы тела и при наличии сопутствующей патологии. Описаны подходы немедикаментозной терапии, основанной на модификации образа жизни с формированием привычек рационального питания и расширением адекватной физической активности. Отмечены критерии эффективности и неэффективности терапии. Приведены рекомендации по ведению дневника питания. Проанализированы особенности назначения лекарственных средств, зарегистрированных для лечения ожирения, перечислены противопоказания и вероятные побочные действия. Представлены данные о влиянии гормонов на массу тела с указанием возможных патогенетических механизмов. Описаны типы бариатрических операций, используемые для хирургического лечения ожирения. Указаны рекомендации Российской ассоциации эндокринологов по наблюдению пациентов после радикального лечения.

Об авторах

Ю. В. Дыдышко
Белорусский государственный медицинский университет, Республиканский центр медицинской реабилитации и бальнеолечения
Беларусь


А. П. Шепелькевич
Белорусский государственный медицинский университет
Беларусь


Список литературы

1. Dedov I.I., Melnichenko G.A. (2006) Obesity: etiology, pathogenesis, clinical aspects. M.: MIA, 456 p.

2. Bray G.A. (2017) Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev., vol. 18(7), pp. 715–723.

3. Prevalence of Obesity [Electronic resource]. Mode of access: https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity. Date of access: 02.03.2020.

4. (2017) Report of the WHO Regional Office for Europe "Prevalence of risk factors for noncommunicable diseases in the Republic of Belarus". Minsk, 250 p.

5. Dedov I.I., Grandfathers I.I., Shestakova M.V., Galstyan G.R. (2016) The prevalence of type 2 diabetes in the adult population of Russia (NATION study). Diabetes mellitus, vol. 19 (2), pp. 104–112.

6. Heymsfield S.B. (2018) Clinical perspectives on obesity treatment: Challenges, gaps, and promising opportunities. NAM Perspectives. Discussion Paper, National Academy of Medicine. Washington, DC. doi: 10.31478/201809b

7. Diseases of the endocrine system, eating disorders and metabolic disorders (E00-E90) [Electronic resource]. https://mkb-10.com/index. php?pid=3001. Date of access: 04/20/2020.

8. Quetelet A. (1835) Sur l’homme Le développement de ses facultés: Essai de physique sociale. Paris: Bachelier, 327 p.

9. (1997) World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO.

10. (2019) Obesity: Clinical Recommendations. Public Organization "Russian Association of Endocrinologists". Moscow: ESC, 36 p.

11. Grandfathers II. (2018) National clinical guidelines for the treatment of morbid obesity in adults. 3rd revision (treatment of morbid obesity in adults). Obesity and metabolism, no 15 (1), pp. 53–70.

12. Pereira-Santos M. (2015) Obesity and vitamin D deficiency: a systematic review and metaanalysis. Obes Rev., vol. 16(4), pp. 341–349.

13. Lotito A. (2017) Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients, vol. 9(3), pii: E241.

14. Daniel E., Newell-Price J. (2017) Cushing’s syndrome. Medicine, vol. 45, Issue 8, pp. 475–479.

15. Auriemma R. (2018) The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab., vol. 13(2), pp. 99–106.

16. Escobar-Morreale H. (2017) Prevalence of ‘obesity-associated gonadal dysfunction’ in severely obese men and women and its resolution after bariatric surgery: a systematic review and metaanalysis. Hum Reprod Update. Jul 1; vol. 23(4), pp. 390–408.

17. Schwarz P.E., Lindström J., Kissimova-Scarbeck K. (2008) The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes, vol. 116, pp. 167–172.

18. Blundell J.E., Dulloo A.G., Salvador J. (2014) On behalf of the EASO SAB Working Group on BMI: Beyond BMI – phenotyping the obesities. Obes Facts, vol. 7, pp. 322–328.

19. Sampsel S., May J. (2007) Assessment and management of obesity and comorbid conditions. Dis Manag., vol. 1, pp. 252–265.

20. Jensen M.D., Ryan D.H., Apovian C.M. (2014) American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation, vol. 129 (suppl 2), pp. S102–S138.

21. Sharma M. (2007) Behavioural interventions for preventing and treating obesity in adults. Obes Rev., vol. 8, pp. 441–449.

22. Lang A., Froelicher E.S. (2006) Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J. Cardiovasc Nurs., vol. 5, pp. 102–114.

23. Solntseva A.V. (2019) Obesity in children: a training manual. Minsk: BSMU, 24 p.

24. Moffitt R., Haynes A., Mohr P. (2015) Treatment beliefs and preferences for psychological therapies for weight management. J. Clin Psychol., vol. 71, pp. 584–596.

25. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract, vol. 22 (Suppl 3).

26. Hainer V., Toplak H., Mitrakou A. (2008) Treatment modalities of obesity: What fits whom? Diabetes Care, vol. 31(suppl 2), pp. S269–S277.

27. Shai I., Schwarzfuchs D., Henkin Y. (2008) For the Dietary Intervention Randomized Controlled Trial (DIRECT) Group: Weight loss with a low- carbohydrate, Mediterranean, or low-fat diet. N Engl J. Med., vol. 359, pp. 229–241.

28. Willis L.H., Slentz C.A., Bateman L.A. (2012) Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J. Appl Physiol., vol. 113, pp. 1831–1837.

29. Stephens S.K., Cobiac L.J., Lennert Veerman. J. (2014) Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Preventive Medicine, vol. 62, pp. 167–178.

30. Pasquali R., Casanueva F., Haluzik M. (2020) European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol., Jan., vol. 182(1), pp. G1–G32.

31. Caroline M. Apovian, Louis J. Aronne, Daniel H. Bessesen (2015) Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. J. Clin Endocrinol Metab, February, vol. 100(2), pp. 342–362.

32. Wadden T.A., Hollander P., Klein S. (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond), vol. 37, pp. 1443–1451.

33. Astrup A., Carraro R., Finer N. (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1analog, liraglutide. Int J. Obes (Lond) [Errata (2012) 36:890 and (2013) 37:322], vol. 36, pp. 843–854.

34. (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract, vol. 22 (Suppl 3). [ADA Diabetes Care 2017; 40 (Suppl 1)], pp. S44–S47.

35. Moran L.J., Pasquali R., Teede H.J. (2009) Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertility and Sterility, vol. 92, pp. 1966–1982.

36. Pucci A., Finer N. (2015) New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol., vol. 31, pp. 142–152.

37. Toplak H., Ziegler O., Keller U. (2005) X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab., vol. 7, pp. 699–708.

38. Instructions for use of the drug Figurin (orlistat) [Electronic resource]. https://lekpharm.by/produkciya/figurin.html. Date of access: 04/20/2020

39. (2016) Vitamin D deficiency in adults: Clinical recommendations. Russian Association of Endocrinologists. Moscow: ESC, 39 p.

40. Curfman G., Morrissey S., Drazen J. (2010) Sibutramine – another flawed diet pill. N Engl J. Med, no 363, pp. 972–4. [James W., Caterson I., Coutinho W. (2010) Effect of sibutramine on cardiovascular outcomes in overweight and obese subject. N. Engl J. Med., no 363, pp. 905–17].

41. Ametov A.S. (2013) Report on the VESNA program. Effectively treating obesity is the way to deal with the Diabetes mellipidus epidemic. Effective pharmacotherapy. Endocrinology. Special issue., pp. 7–11.

42. Marso S.P., Daniels G.H., Brown-Frandsen K. (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl J. Med., vol. 375, pp. 311–322.

43. le Roux C.W., Astrup A., Fujioka K. (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, doubleblind trial. Lancet, vol. 389(10077), pp. 1399–1409.

44. Marzullo P., Minocci A., Mele C. (2018) The relationship between resting energy expenditure and thyroid hormones in response to short-term weight loss in severe obesity. PLoS ONE, 13 e0205293.

45. Krzizek E.C., Brix J.M., Herz C.T (2018) Prevalence of micronutrient deficiency in patients with morbid obesity before bariatric surgery. Obesity Surgery, vol. 28, pp. 643–648.

46. Ong M.W., Tan C.H., Cheng A.K.S. (2018) Prevalence and determinants of vitamin D deficiency among the overweight and obese Singaporeans seeking weight management including bariatric surgery: a relationship with bone health. Obesity Surgery, vol. 28, pp. 2305–2312.

47. Hewitt S., Aasheim E.T., Sovik T.T. (2018) Relationships of serum 25-hydroxyvitamin D, ionized calcium and parathyroid hormone after obesity surgery. Clinical Endocrinology, vol. 88, pp. 372–379.

48. Walsh J.S., Bowles S. & Evans A.L. (2017) Vitamin D in obesity. Current Opinion in Endocrinology, Diabetes, and Obesity, vol. 24, pp. 389–394.

49. Drincic A., Fuller E., Heaney R.P. (2013) 25-Hydroxyvitamin D Response to Graded Vitamin D3 Supplementation Among Obese Adults. J. Clin Endocrinol Metab, vol. 98(12), pp. 4845–4851.

50. Bassatne A., Chakhtoura M., Saad R., Fuleihan G.E. (2019) Vitamin D supplementation in obesity and during weight loss: a review of randomized controlled trials. Metabolism: Clinical and Experimental, vol. 92, pp. 193–205.


Для цитирования:


Дыдышко Ю.В., Шепелькевич А.П. Ожирение: современные возможности лечения у взрослых. Рецепт. 2020;(2-3):342-361. https://doi.org/10.34883/PI.2020.2.2.041

For citation:


Dydyshka .Y., Shepelkevich .A. Obesity: Current Treatment Options in Adults. Recipe. 2020;(2-3):342-361. (In Russ.) https://doi.org/10.34883/PI.2020.2.2.041

Просмотров: 19


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1993-4882 (Print)
ISSN 2414-2263 (Online)